Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial ( SYNCHRONIZE ™‐1)
Authors' conclusion
SYNCHRONIZE-1 will determine the efficacy, safety, and tolerability of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for weight loss in a representative cohort of people with obesity without T2D.
Study context
- Population
- Adults aged ≥18 years with BMI ≥30 or ≥27 kg/m² with ≥1 obesity complication, without T2D; 14 countries
- Participants
- 725 adults14 countries
- Comparison
- Once-weekly subcutaneous survodutide vs placebo
- Primary endpoint
- Percent body weight change and achievement of body weight reduction ≥5% from baseline
- Follow-up
- Week 76
Methodological detailsmultinational, double-blind, placebo-controlled, phase 3, randomized 1:1:1
- Multinational
- Double-blind
- Placebo-controlled
- Phase 3
- Randomized 1:1:1
Primary result
As reported in the abstract
Baseline characteristics
- Mean age
- 47.1 years
- Mean BMI
- 37.9 kg/m²
- Mean waist circumference
- 115.2 cm
- Female
- 59.4%
- From North America
- 47.3%
- From Europe
- 21.0%
- From East Asia
- 20.0%
- Hypertension
- 40.0%
- Dyslipidaemia
- 33.7%
- Prediabetes
- 30.2%
- Mean HbA1c
- 5.5%
- Mean eGFR
- 93.0 mL/min/1.73 m²
- Mean systolic/diastolic blood pressure
- 127.0/82.7 mmHg
- Mean LDL-C
- 116.4 mg/dL
- Taking lipid-lowering drugs
- 21.8%
Original publication
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial ( SYNCHRONIZE ™‐1). Diabetes Obes Metab. Published 4 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →